Business Context and Reporting Period
Company: Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company focused on cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases.
Filing Date: March 4, 2022 (Form 8-K).
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) with Runway Growth Finance Corp.
Key Financial Metrics and Transaction Details
Debt Financing:
- Total Loan Commitment: $75.0 million.
- Initial Funding: $30.0 million funded on the Closing Date.
- Contingent Funding: Remaining $45.0 million fundable upon achievement of predetermined milestones.
- Maturity Date: April 15, 2027.
- Interest Rate: Variable annual rate of 8.75% plus the greater of 0.50% or the three-month LIBOR rate, with a floor of 9.25%.
- Repayment Terms: Interest-only payments from March 15, 2022, until April 1, 2024 (extendable to April 1, 2025 upon milestone achievement). Principal and interest payments commence thereafter.
Equity Component:
- Warrant Issuance: Warrant to purchase 748,036 shares of common stock.
- Exercise Price: $0.8021 per share.
- Term: 10 years from issuance.
Collateral: Lien on substantially all assets, excluding Intellectual Property and Excluded Collateral.
Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, profit, operating cash flow, or margins.
Material Changes and Covenants
Use of Proceeds: Support ongoing clinical development of investigational product candidates and general working capital.
Covenants: The agreement includes customary covenants regarding liquidity, financial reporting, and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers, acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries.
Events of Default: Include failure to make payments, breach of covenants, material adverse effects, insolvency, bankruptcy, or judgments/fines exceeding $500,000.
Guidance, Risks, and Contingencies
Management Commentary: The financing is intended to support the company's pipeline development.
Risks and Contingencies:
- Milestone Dependency: Access to the remaining $45.0 million of the loan is contingent on achieving specific milestones.
- Amortization Extension: Extension of the interest-only period to 2025 is contingent on milestone achievement.
- Prepayment: Mustang may prepay the loan with 10 days' notice, subject to a Prepayment Fee and Final Payment.
- Enforcement: Runway may accelerate amounts due upon an event of default.
Investor Verification Checklist
- Verify the specific milestones required to unlock the remaining $45.0 million in funding.
- Confirm the exact calculation of the "Prepayment Fee" and "Final Payment" defined in the Loan Agreement.
- Review the definition of "Excluded Collateral" to understand the scope of assets not subject to the lien.
- Assess the company's current cash runway relative to the $30.0 million initial funding and projected burn rate.
- Monitor the dilution impact of the warrant exercise (748,036 shares at $0.8021) if exercised.